skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Is MOH the superior choice in its space? Would you buy now for the next 5 years?
Thanks!
Read Answer Asked by David on June 27, 2024
Q: Thomson Reuters via LSEG Stock Report Plus (on the iTrade platform) gives LLY-N an Average Score of 4 out of 10. From my perspective, this is a low score given the momentum in the stock price of LLY-N. Any insights about this conundrum, at least in my mind?.....As it makes me wonder about continuing to hold a small position in LLY-N.....Thanks......Tom
Read Answer Asked by Tom on June 25, 2024
Q: Hi 5i, been watching TMO for a bit, any news as to why it's off 2.5% today? Does it have to do with markets view on Olink purchase? What are the next few years forecast for growth and what would be a good entry point? Thx
Read Answer Asked by Christopher on June 24, 2024
Q: I have held JNJ for years and I am *STILL* holding on , in the [vain] hope that surely management will FINALLY resolve its various self-inflicted legal problems. I have been MISERABLY wrong. JNJ shares continue to decline (drowning is the perception as we focus much more on loss). I was idiot enough to buy into JNJ’s spin off KVUE, on which I have a rather loss in just one year.

Notwithstanding the enthusiasm of media commentators, the health care sector hasn’t done anything outside of a couple of star-companies. Are JNJ and KVUE worth holding on to? I would appreciate very much your substance-backed reasons either way. In your answer, kindly please put less emphasis on the legal issues which are already well known and focus entirely on the future prospects .
Many thanks.

Read Answer Asked by Adam on June 21, 2024
Q: My health sector holdings consist of ABBV and IHI, both in a non-registered account. Neither have been stellar performers lately, but both are still up (ABBV by 28%, IHI by 50%). I have my eye on LLY, but the tax consequences of trimming or selling either ABBV or IHI are making me think twice. What would you do in my position? Thank you.
Read Answer Asked by Maureen on June 20, 2024
Q: I had a partial fill on a buy order for PFE and did not return to top up my holding . My position is too small to leave as is and I am unsure whether to add to the position or exit entirely. PFE is included in various dividend models, e.g. the AAII Dividend portfolio and the MS Global Dividend model. This prompted me to hang on. So did the many words by financial writers and commentators who have almost all been talking-up the health care sector for at least a year. Most comments by financial professionals and analysts are on how and why they expect the health care sector finally to catch up. Their focus on demographics does make sense. Yet, nothing happens to liven up the shares in pharma businesses, outside of a few stars like LLY and NVO. The share price of PFE itself has done nothing but decline. Do you the company has good prospects— good enough to ADD to the position? Or do you think I should just exit and be done with it ? (And give up on all the darn reading as research often gets one nowhere).
Read Answer Asked by Adam on June 20, 2024
Q: Hi 5i, I have held Medtronic for just over 3 years and am down 30%. Do you think it's worth holding another year or two (as do a number of the analysts) or should I cut bait and redeploy the funds into LLY? Other suggestions are welcome. Do you feel Intuitive Surgical is overvalued or a good long term call? Thanks!
Read Answer Asked by Martha on June 20, 2024
Q: Would you recommend to buy, hold, or sell GSK?

I ask on behalf of a relative I help with investing. GSK is currently 1.3% of their portfolio. I had already been thinking of recommending that they sell when the news on June 3 came out:

"Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker."

They are at a 15% loss with their GSK holding (less if you consider dividends), but luckily it is a small part of the portfolio.

I am leaning toward a 'sell recommendation' but am open to counter arguments.

Thanks so much!
Read Answer Asked by Robert on June 18, 2024
Q: hi group i am very light on financials does it make sense to invest in the smaller companies for exposure to the financial sector. (eg GSY,IFC EQB - please rate these 3 (in order of preference and why.-against CAD/US BANKS .. also I am light on Health care do you see the sectors as a buy please give me you top 3 picks in healthcare presently i own CVS and PFE should i sell them to invest in you picks?...Thanks for you help with this
Read Answer Asked by Terence on June 14, 2024
Q: Just sold some Apple stock for two reasons. One, because the position was too large and two my potion in high tech stocks is also too high.
Need to redeploy the funds to healthcare I’m thinking of NVO or LLY.
What would you recommend and an entry point as well as the reason for the choice.

Thanks to the 5i team

Joe
Read Answer Asked by Joe on June 13, 2024
Q: I am interested to invest in the US health sector. Could you please suggest the best pharmaceutical companies in the market or companies related to the health sector? Thank you.
Read Answer Asked by Esther on June 12, 2024
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!